^
    2ms
    SPOTLIGHT: A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines (clinicaltrials.gov)
    P1/2, N=27, Terminated, Jasper Therapeutics, Inc. | Trial completion date: Nov 2025 --> Jul 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2025 --> Jul 2025; Enrollment was completed and primary efficacy endpoint was completed. Study was terminated before safety follow up was completed due to changes in company priorities and not related to safety concerns
    Trial completion date • Trial termination • Trial primary completion date
    |
    briquilimab (JSP191)
    3ms
    A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma (clinicaltrials.gov)
    P1, N=17, Terminated, Jasper Therapeutics, Inc. | N=30 --> 17 | Active, not recruiting --> Terminated; Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns.
    Enrollment change • Trial termination
    |
    briquilimab (JSP191)
    3ms
    Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD) (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting --> Active, not recruiting | N=38 --> 7
    Enrollment closed • Enrollment change
    |
    briquilimab (JSP191)
    4ms
    A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Jasper Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2025 --> Aug 2025
    Enrollment closed • Trial primary completion date
    |
    briquilimab (JSP191)
    4ms
    JSP191 Antibody Targeting Conditioning in SCID Patients (clinicaltrials.gov)
    P1/2, N=23, Terminated, Jasper Therapeutics, Inc. | N=40 --> 23 | Trial completion date: Jun 2028 --> Jul 2025 | Active, not recruiting --> Terminated; Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns.
    Enrollment change • Trial completion date • Trial termination
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IL7R (Interleukin 7 Receptor) • JAK3 (Janus Kinase 3) • RAG1 (Recombination Activating 1)
    |
    briquilimab (JSP191)
    7ms
    SPOTLIGHT: A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines (clinicaltrials.gov)
    P1/2, N=27, Active, not recruiting, Jasper Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    briquilimab (JSP191)
    8ms
    Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD) (clinicaltrials.gov)
    P1, N=38, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Recruiting
    Enrollment open
    |
    briquilimab (JSP191)
    8ms
    JSP191 Antibody Targeting Conditioning in SCID Patients (clinicaltrials.gov)
    P1/2, N=40, Active, not recruiting, Jasper Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IL7R (Interleukin 7 Receptor) • JAK3 (Janus Kinase 3) • RAG1 (Recombination Activating 1)
    |
    briquilimab (JSP191)
    9ms
    Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function (clinicaltrials.gov)
    P1/2, N=6, Active, not recruiting, National Heart, Lung, and Blood Institute (NHLBI) | N=72 --> 6 | Trial completion date: Mar 2033 --> Nov 2027 | Trial primary completion date: Sep 2032 --> Nov 2025 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    Campath (alemtuzumab) • sirolimus • briquilimab (JSP191)
    9ms
    Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia (clinicaltrials.gov)
    P1/2, N=40, Active, not recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Recruiting --> Active, not recruiting | N=90 --> 40 | Trial completion date: Nov 2033 --> Jan 2027 | Trial primary completion date: Nov 2032 --> Jan 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD14 (CD14 Molecule)
    |
    Campath (alemtuzumab) • sirolimus • hydroxyurea • Neupogen (filgrastim) • briquilimab (JSP191) • plerixafor
    9ms
    Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD) (clinicaltrials.gov)
    P1, N=38, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    briquilimab (JSP191)
    9ms
    JSP191 (briquilimab) in Subjects with LR-MDS (clinicaltrials.gov)
    P1, N=6, Terminated, Jasper Therapeutics, Inc. | N=30 --> 6 | Trial completion date: Jul 2025 --> Oct 2024 | Recruiting --> Terminated; The study was terminated due to a lack of improvement in clinical efficacy outcomes.
    Enrollment change • Trial completion date • Trial termination
    |
    briquilimab (JSP191)